氨苯砜在临床前大疱性类天疱疮小鼠模型中抑制疾病
该研究评估氨苯砜在获得性大疱性表皮松解症和黏膜类天疱疮抗体转移小鼠模型中的疗效。氨苯砜显著减轻两种模型的炎症,减少中性粒细胞募集并抑制其释放LTB4和ROS,提示其作用机制可能基于此。
要点
- 氨苯砜在两种自身免疫性大疱病小鼠模型中显著减轻炎症。
- 氨苯砜减少中性粒细胞向皮肤募集并抑制LTB4和ROS释放。
- 氨苯砜可能作为非特异性LTB4生物合成抑制剂用于其他LTB4驱动疾病。
核心结论
- 氨苯砜在获得性大疱性表皮松解症和黏膜类天疱疮小鼠模型中显著减轻炎症,其作用机制可能基于抑制中性粒细胞释放LTB4和ROS。
研究设计与样本
- 研究采用抗体转移小鼠模型评估氨苯砜对获得性大疱性表皮松解症和黏膜类天疱疮的效果,该模型不能得出临床治疗方案结论。
主要发现
- 氨苯砜显著减轻两种模型的炎症,减少中性粒细胞向皮肤募集,并破坏其响应免疫复合物释放LTB4和ROS。
临床怎么用
- 氨苯砜可能作为非特异性LTB4生物合成抑制剂,鼓励在其它LTB4驱动疾病中测试其疗效。
局限性
- 抗体转移小鼠模型不能得出关于临床治疗方案的结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epidermolysis bullosa acquisita and mucous membrane pemphigoid are autoimmune blistering diseases characterized by mucocutaneous blisters elicited by an autoantibody-mediated immune response against specific proteins of the epidermal basement membrane. The antibiotic dapsone is frequently used to treat both diseases, but its therapeutic effectiveness is uncertain, and its mode of action in these diseases is largely unknown. We evaluated the effect of dapsone in antibody transfer mouse models of epidermolysis bullosa acquisita and mucous membrane pemphigoid, which do not allow the drawing of conclusions on clinical treatment regimens but can be instrumental to partially uncover the mode(s) of action of dapsone in these diseases. Dapsone significantly mitigated inflammation in both models, reducing the recruitment of neutrophils into the skin and disrupting their release of leukotriene B4 (LTB4) and ROS in response to immune complexes. LTB4 has been implicated in numerous diseases, but effective LTB4 inhibitors for clinical use are not available. Our findings indicate that the mode of action of dapsone in these models may be based on the inhibition of LTB4 and ROS release from neutrophils. Moreover, they encourage testing the use of dapsone as an effective, albeit nonspecific, inhibitor of LTB4 biosynthesis in other LTB4-driven diseases.
引用
- Murthy S, Schilf P, Patzelt S, et al. Dapsone Suppresses Disease in Preclinical Murine Models of Pemphigoid Diseases. J Invest Dermatol. 2021. PMID: 34033839. doi:10.1016/j.jid.2021.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。